Header Logo

Connection

Elliott Mufson to Humans

This is a "connection" page, showing publications Elliott Mufson has written about Humans.
Connection Strength

0.274
  1. Hippocampal proNGF signaling pathways and ?-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 2012 Nov; 71(11):1018-29.
    View in: PubMed
    Score: 0.022
  2. A novel approach for long-term oral drug administration in animal research. J Neurosci Methods. 2011 Feb 15; 195(2):194-9.
    View in: PubMed
    Score: 0.020
  3. Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis. 2010; 7(1-3):139-42.
    View in: PubMed
    Score: 0.019
  4. Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol. 2003 Aug 25; 463(3):341-57.
    View in: PubMed
    Score: 0.012
  5. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2003 Aug; 60(8):1143-8.
    View in: PubMed
    Score: 0.012
  6. Vesicular Glutamate Transporter Changes in the Cortical Default Mode Network During the Clinical and Pathological Progression of Alzheimer's Disease. J Alzheimers Dis. 2023; 94(1):227-246.
    View in: PubMed
    Score: 0.011
  7. Co-expression network analysis of frontal cortex during the progression of Alzheimer's disease. Cereb Cortex. 2022 11 09; 32(22):5108-5120.
    View in: PubMed
    Score: 0.011
  8. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
    View in: PubMed
    Score: 0.011
  9. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb; 51(2):145-55.
    View in: PubMed
    Score: 0.011
  10. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001 Feb; 49(2):202-13.
    View in: PubMed
    Score: 0.010
  11. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 2000 Nov 06; 427(1):19-30.
    View in: PubMed
    Score: 0.010
  12. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999 Aug; 158(2):469-90.
    View in: PubMed
    Score: 0.009
  13. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol. 1999 Feb; 57(4):451-84.
    View in: PubMed
    Score: 0.009
  14. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. J Clin Invest. 2018 10 01; 128(10):4297-4312.
    View in: PubMed
    Score: 0.008
  15. Retrograde transport of brain-derived neurotrophic factor (BDNF) following infusion in neo- and limbic cortex in rat: relationship to BDNF mRNA expressing neurons. J Comp Neurol. 1996 Nov 18; 375(3):417-44.
    View in: PubMed
    Score: 0.007
  16. Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2015; 47(2):385-402.
    View in: PubMed
    Score: 0.007
  17. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat. Exp Neurol. 1994 Sep; 129(1):15-26.
    View in: PubMed
    Score: 0.006
  18. Evidence for Alzheimer's disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct Funct. 2015 Nov; 220(6):3143-65.
    View in: PubMed
    Score: 0.006
  19. Cortical pyroglutamate amyloid-? levels and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2015 Jan; 36(1):12-9.
    View in: PubMed
    Score: 0.006
  20. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.005
  21. MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol Aging. 2011 Oct; 32(10):1756-64.
    View in: PubMed
    Score: 0.005
  22. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A. 2009 Jul 28; 106(30):12483-8.
    View in: PubMed
    Score: 0.004
  23. Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology. J Alzheimers Dis. 2008 Feb; 13(1):53-66.
    View in: PubMed
    Score: 0.004
  24. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.004
  25. Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol. 2007 Apr; 170(4):1200-9.
    View in: PubMed
    Score: 0.004
  26. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology. 2007 Mar 06; 68(10):757-63.
    View in: PubMed
    Score: 0.004
  27. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.003
  28. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 May; 11(5):551-5.
    View in: PubMed
    Score: 0.003
  29. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch Neurol. 2005 Mar; 62(3):425-30.
    View in: PubMed
    Score: 0.003
  30. Decreases in soluble alpha-synuclein in frontal cortex correlate with cognitive decline in the elderly. Neurosci Lett. 2004 Apr 08; 359(1-2):104-8.
    View in: PubMed
    Score: 0.003
  31. Contribution of changes in ubiquitin and myelin basic protein to age-related cognitive decline. Neurosci Res. 2004 Jan; 48(1):93-100.
    View in: PubMed
    Score: 0.003
  32. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003 Feb; 5(1):39-48.
    View in: PubMed
    Score: 0.003
  33. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.003
  34. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002 Feb; 51(2):182-9.
    View in: PubMed
    Score: 0.003
  35. Improved detection of substantia nigra pathology in Alzheimer's disease. J Histochem Cytochem. 2002 Jan; 50(1):99-106.
    View in: PubMed
    Score: 0.003
  36. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2001 Aug 27; 437(3):296-307.
    View in: PubMed
    Score: 0.003
  37. Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem. 2000 Dec; 48(12):1627-38.
    View in: PubMed
    Score: 0.002
  38. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 1999 Sep 06; 411(4):693-704.
    View in: PubMed
    Score: 0.002
  39. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999 Sep; 46(3):419-24.
    View in: PubMed
    Score: 0.002
  40. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.